Intracerebroventricular administration of oxytocin and intranasal administration of the oxytocin derivative improve β‐amyloid peptide (25–35)‐induced memory impairment in mice

• Published in: Neuropsychopharmacology reports Vol. 42; no. 4; pp. 492 - 501
• Main Authors: Takahashi, Junpei, Ueta, Yudai, Yamada, Daisuke, Sasaki‐Hamada, Sachie, Iwai, Takashi, Akita, Tomomi, Yamashita, Chikamasa, Saitoh, Akiyoshi, Oka, Jun‐Ichiro
• Format: Journal Article
• Language: English
• Published: United States John Wiley & Sons, Inc 01.12.2022; Wiley
• Subjects: Administration, Intranasal; Alzheimer Disease - chemically induced; Alzheimer Disease - drug therapy; Alzheimer's disease; amnesia; Amyloid beta-Peptides; Animal cognition; Animals; Brain; brain drug delivery and targeting; intranasal administration; Memory; Memory Disorders - chemically induced; Memory Disorders - drug therapy; Mice; oxytocin; Oxytocin - adverse effects; Peptides; spatial memory; β‐amyloid peptide (25–35); Japan; amnesia; oxytocin; β-amyloid peptide (25-35); intranasal administration; spatial memory; brain drug delivery and targeting

Aim We previously reported that oxytocin, a peptide hormone, can reverse the β‐amyloid peptide (25–35) (Aβ25–35)‐induced impairments of the murine hippocampal synaptic plasticity. In this study, we examined the effects of oxytocin on the Aβ25–35‐induced impairment of cognitive behavior in murine in...